X4 Pharmaceuticals, Inc.
XFORNASDAQHealthcare● Active
$3.88
+$0.17(+4.58%)
Market Cap$365960420
P/E Ratio—
52W High$4.83
52W Low$1.35
X4 Pharmaceuticals, Inc. (XFOR) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · XFOR · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($79.20M) | ($37.45M) | ($101.17M) | ($93.87M) | ($88.70M) |
| Depreciation & Amort. | $1.28M | $0.80M | $0.42M | $0.51M | $1.89M |
| Stock-Based Comp. | $4.30M | $8.20M | $8.69M | $5.20M | $0.00M |
| Change in Working Capital | ($2.58M) | $2.67M | $0.34M | $5.74M | ($1.50M) |
| Net Cash from Operations | ($85.62M) | ($130.90M) | ($96.51M) | ($77.10M) | ($70.91M) |
| Investing Activities | |||||
| Capital Expenditure | ($3.00M) | ($7.33M) | ($0.06M) | ($0.10M) | ($0.61M) |
| Purchases of Investments | ($63.39M) | ($57.13M) | ($16.82M) | $0.00M | $0.00M |
| Sales of Investments | $74.54M | $26.45M | $2.00M | $0.00M | $0.00M |
| Net Cash from Investing | $8.15M | $66.99M | ($14.88M) | ($0.10M) | ($0.61M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | ($2.00M) |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $20.00M | $20.44M | ($0.80M) | $0.00M |
| Net Cash from Financing | $238.63M | $20.29M | $88.52M | $117.23M | $74.25M |
| Free Cash Flow | |||||
| Free Cash Flow | ($88.62M) | ($138.23M) | ($96.57M) | ($77.20M) | ($71.52M) |
| FCF Margin %(computed) | -252.38% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more X4 Pharmaceuticals, Inc. data
About X4 Pharmaceuticals, Inc. (XFOR) Cash Flow Statement
X4 Pharmaceuticals, Inc. generated operating cash flow of ($0.09B) and free cash flow of ($0.09B) for 2025 — a FCF margin of -252.38%. Capital expenditure was ($0.00B).
Frequently asked questions
XFOR · 4 questionsX4 Pharmaceuticals, Inc. generated free cash flow of ($0.09B) for 2025, up 35.9% year-over-year.
XFOR free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10